NASDAQ:UCBB

US-China Biomedical Technology Competitors

$0.34

+0.21 (+169.84 %)

(As of 04/19/2021 11:30 AM ET)

Add

Compare

Today's Range

$0.34

Now: $0.34▼

$0.34

50-Day Range

$0.10

MA: $0.18▼

$0.35

52-Week Range

$0.01

Now: $0.34▼

$0.35

Volume187 shs

Average Volume1,063 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

US-China Biomedical Technology (NASDAQ:UCBB) Vs. AAPL, MSFT, GOOG, GOOGL, FB, and TSM

Should you be buying UCBB stock or one of its competitors? Companies in the sector of "computer and technology" are considered alternatives and competitors to US-China Biomedical Technology, including Apple (AAPL), Microsoft (MSFT), Alphabet (GOOG), Alphabet (GOOGL), Facebook (FB), and Taiwan Semiconductor Manufacturing (TSM).

US-China Biomedical Technology vs. Apple Stock

US-China Biomedical Technology (NASDAQ:UCBB) and Apple (NASDAQ:AAPL) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares US-China Biomedical Technology and Apple's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
US-China Biomedical Technology	N/A	N/A	N/A	N/A	N/A
Apple	$274.52 billion	8.24	$57.41 billion	$3.28	41.06

Apple has higher revenue and earnings than US-China Biomedical Technology.

Analyst Ratings

This is a breakdown of recent ratings and price targets for US-China Biomedical Technology and Apple, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
US-China Biomedical Technology	0	0	0	0	N/A
Apple	2	8	27	0	2.68

Apple has a consensus target price of $137.0058, indicating a potential upside of 1.31%. Given Apple's higher probable upside, analysts clearly believe Apple is more favorable than US-China Biomedical Technology.

Profitability

This table compares US-China Biomedical Technology and Apple's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
US-China Biomedical Technology	N/A	N/A	N/A
Apple	20.91%	75.15%	17.63%

Institutional & Insider Ownership

57.8% of Apple shares are held by institutional investors. 0.1% of Apple shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Apple beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.

US-China Biomedical Technology vs. Microsoft Stock

US-China Biomedical Technology (NASDAQ:UCBB) and Microsoft (NASDAQ:MSFT) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for US-China Biomedical Technology and Microsoft, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
US-China Biomedical Technology	0	0	0	0	N/A
Microsoft	0	2	29	2	3.00

Microsoft has a consensus price target of $269.9867, suggesting a potential upside of 3.98%. Given Microsoft's higher possible upside, analysts clearly believe Microsoft is more favorable than US-China Biomedical Technology.

Earnings & Valuation

This table compares US-China Biomedical Technology and Microsoft's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
US-China Biomedical Technology	N/A	N/A	N/A	N/A	N/A
Microsoft	$143.02 billion	13.68	$44.28 billion	$5.76	45.03

Microsoft has higher revenue and earnings than US-China Biomedical Technology.

Profitability

This table compares US-China Biomedical Technology and Microsoft's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
US-China Biomedical Technology	N/A	N/A	N/A
Microsoft	32.28%	40.74%	16.23%

Insider & Institutional Ownership

69.0% of Microsoft shares are held by institutional investors. 0.1% of Microsoft shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Microsoft beats US-China Biomedical Technology on 9 of the 9 factors compared between the two stocks.

US-China Biomedical Technology vs. Alphabet Stock

US-China Biomedical Technology (NASDAQ:UCBB) and Alphabet (NASDAQ:GOOG) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Profitability

This table compares US-China Biomedical Technology and Alphabet's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
US-China Biomedical Technology	N/A	N/A	N/A
Alphabet	20.80%	17.31%	12.68%

Insider & Institutional Ownership

31.9% of Alphabet shares are owned by institutional investors. 13.0% of Alphabet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for US-China Biomedical Technology and Alphabet, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
US-China Biomedical Technology	0	0	0	0	N/A
Alphabet	0	1	21	0	2.95

Alphabet has a consensus price target of $2,334.0556, suggesting a potential upside of 1.35%. Given Alphabet's higher possible upside, analysts plainly believe Alphabet is more favorable than US-China Biomedical Technology.

Earnings and Valuation

This table compares US-China Biomedical Technology and Alphabet's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
US-China Biomedical Technology	N/A	N/A	N/A	N/A	N/A
Alphabet	$161.86 billion	9.59	$34.34 billion	$51.56	44.63

Alphabet has higher revenue and earnings than US-China Biomedical Technology.

Summary

Alphabet beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.

US-China Biomedical Technology vs. Alphabet Stock

US-China Biomedical Technology (NASDAQ:UCBB) and Alphabet (NASDAQ:GOOGL) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Institutional and Insider Ownership

33.8% of Alphabet shares are owned by institutional investors. 13.2% of Alphabet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares US-China Biomedical Technology and Alphabet's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
US-China Biomedical Technology	N/A	N/A	N/A
Alphabet	20.80%	17.31%	12.68%

Analyst Recommendations

This is a breakdown of current ratings for US-China Biomedical Technology and Alphabet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
US-China Biomedical Technology	0	0	0	0	N/A
Alphabet	0	1	40	0	2.98

Alphabet has a consensus target price of $2,159.9512, indicating a potential downside of 5.71%. Given Alphabet's higher probable upside, analysts plainly believe Alphabet is more favorable than US-China Biomedical Technology.

Valuation and Earnings

This table compares US-China Biomedical Technology and Alphabet's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
US-China Biomedical Technology	N/A	N/A	N/A	N/A	N/A
Alphabet	$161.86 billion	9.53	$34.34 billion	$51.56	44.37

Alphabet has higher revenue and earnings than US-China Biomedical Technology.

Summary

Alphabet beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.

US-China Biomedical Technology vs. Facebook Stock

Facebook (NASDAQ:FB) and US-China Biomedical Technology (NASDAQ:UCBB) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Facebook and US-China Biomedical Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Facebook	1	5	36	1	2.86
US-China Biomedical Technology	0	0	0	0	N/A

Facebook presently has a consensus target price of $327.2564, indicating a potential upside of 8.76%. Given Facebook's higher probable upside, equities research analysts plainly believe Facebook is more favorable than US-China Biomedical Technology.

Institutional and Insider Ownership

65.0% of Facebook shares are owned by institutional investors. 14.1% of Facebook shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Facebook and US-China Biomedical Technology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Facebook	32.00%	23.27%	18.12%
US-China Biomedical Technology	N/A	N/A	N/A

Earnings and Valuation

This table compares Facebook and US-China Biomedical Technology's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Facebook	$70.70 billion	12.09	$18.49 billion	$6.43	46.67
US-China Biomedical Technology	N/A	N/A	N/A	N/A	N/A

Facebook has higher revenue and earnings than US-China Biomedical Technology.

Summary

Facebook beats US-China Biomedical Technology on 9 of the 9 factors compared between the two stocks.

US-China Biomedical Technology vs. Taiwan Semiconductor Manufacturing Stock

Taiwan Semiconductor Manufacturing (NYSE:TSM) and US-China Biomedical Technology (NASDAQ:UCBB) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Institutional and Insider Ownership

18.3% of Taiwan Semiconductor Manufacturing shares are owned by institutional investors. 1.1% of Taiwan Semiconductor Manufacturing shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Taiwan Semiconductor Manufacturing and US-China Biomedical Technology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taiwan Semiconductor Manufacturing	37.94%	28.73%	20.16%
US-China Biomedical Technology	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and target prices for Taiwan Semiconductor Manufacturing and US-China Biomedical Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taiwan Semiconductor Manufacturing	2	1	6	0	2.44
US-China Biomedical Technology	0	0	0	0	N/A

Taiwan Semiconductor Manufacturing currently has a consensus price target of $106.75, indicating a potential downside of 8.17%. Given Taiwan Semiconductor Manufacturing's higher probable upside, analysts clearly believe Taiwan Semiconductor Manufacturing is more favorable than US-China Biomedical Technology.

Earnings & Valuation

This table compares Taiwan Semiconductor Manufacturing and US-China Biomedical Technology's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taiwan Semiconductor Manufacturing	$34.63 billion	17.32	$11.83 billion	$3.39	34.12
US-China Biomedical Technology	N/A	N/A	N/A	N/A	N/A

Taiwan Semiconductor Manufacturing has higher revenue and earnings than US-China Biomedical Technology.

Summary

Taiwan Semiconductor Manufacturing beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.